Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy - The Losartan Intervention for Endpoint (LIFE) Reduction in Hypertension Study

Article

关键词: CARDIOVASCULAR MORBIDITY;    PROGNOSTIC-SIGNIFICANCE;    AMERICAN-INDIANS;    RANDOMIZED TRIAL;    BLOOD-PRESSURE;    MASS;    HEART;    MORTALITY;    DISEASE;    VOLTAGE;   

DOI  :  10.1161/CIRCULATIONAHA.105.574822

来源: SCIE

【 摘 要 】

Background - Diabetes mellitus is associated with increased cardiovascular ( CV) morbidity and mortality and with greater ECG left ventricular hypertrophy (LVH); however, it is unclear whether diabetes attenuates regression of hypertensive LVH and whether regression of ECG LVH has similar prognostic value in diabetic and nondiabetic hypertensive individuals. Methods and Results - A total of 9193 hypertensive patients ( 1195 with diabetes) in the Losartan Intervention For Endpoint ( LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end. ECG LVH was defined with gender-adjusted Cornell voltage-duration product (CP) criteria > 2440 mm . ms. After a mean follow-up of 4.8 +/- 0.9 years, patients with diabetes had less regression of CP LVH ( - 138 +/- 866 versus - 204 +/- 854 mm . ms, P < 0.001), remained more likely to have LVH by CP ( 56.0% versus 48.1%, P < 0.001), and had higher rates of CV death, myocardial infarction, stroke, and all-cause mortality and of the LIFE composite end point of CV death, myocardial infarction, or stroke. In multivariable Cox proportional hazards models, in-treatment regression or absence of ECG LVH by CP was associated with between 17% and 35% reductions in event rates in patients without diabetes but did not significantly predict outcome in patients with diabetes. Conclusions - Hypertensive patients with diabetes have less regression of CP LVH in response to antihypertensive therapy than patients without diabetes, and regression of ECG LVH is less useful as a surrogate marker of outcomes in hypertensive patients with diabetes. These findings may in part explain the higher CV morbidity and mortality in hypertensive patients with diabetes, and the absence of a demonstrable improvement in prognosis in diabetic patients in response to regression of ECG LVH suggests a more complex interrelation between underlying LV structural and functional abnormalities and outcome in these patients.

【 授权许可】

Free